Anordrin Eliminates Tamoxifen Side Effects without Changing Its Antitumor Activity

Area of Science:

• Oncology
• Pharmacology
• Hepatology

Background:

• Tamoxifen is crucial for estrogen receptor-positive (ER+) breast cancer but causes uterine and liver toxicities.
• Extended tamoxifen use increases breast cancer protection but exacerbates side effects.
• Current treatment limitations necessitate strategies to mitigate tamoxifen's adverse effects.

Purpose of the Study:

• To investigate anordrin's potential to mitigate tamoxifen-induced side effects.
• To evaluate anordrin's impact on endometrial and liver health during tamoxifen therapy.
• To determine if anordrin affects tamoxifen's anti-cancer activity.

Main Methods:

• Anordrin administration in mouse models undergoing tamoxifen treatment.
• Assessment of endometrial epithelial cell mitosis and non-alcoholic fatty liver disease (NAFLD) markers.
• Analysis of anordiol's binding affinity to ER-α and its effect on the estrogen nuclear pathway.
• Evaluation of tamoxifen's anti-tumor activity in the presence of anordrin in nude mice.

Main Results:

• Anordrin inhibited tamoxifen-induced endometrial cell proliferation and NAFLD in mice.
• Anordrin acted as an anti-estrogenic agent in the uterus and estrogenic in the liver.
• Anordiol exhibited weak binding to ER-α and did not interfere with the classic estrogen pathway.
• Anordrin did not compromise tamoxifen's anti-tumor efficacy against ER+ breast cancer.

Conclusions:

• Anordrin effectively reduces tamoxifen-associated endometrial and liver toxicities.
• Anordrin preserves the anti-tumor activity of tamoxifen, suggesting a synergistic therapeutic potential.
• Anordrin represents a promising agent for managing side effects in long-term tamoxifen therapy for breast cancer.